Tag archive for ‘Immuno-oncology’
ImmunoCellular Therapeutics: Is There an Investment Case to be Made? (IMUC, $0.57)
Investment Background The purpose of this report is to get investors re-engaged with ImmunoCellular Therapeutics (IMUC). On December 11, 2013 the Company announced that ICT-107 did not reach the primary endpoint of median overall survival in a randomized phase 2 trial of 124 patients with newly diagnosed glioblastoma multiforme (ndGBM). The stock plummeted from $2.72 on […]
Immuno-Oncology Promises to be the Next “Big Thing” In Biotechnology
Immuno-Oncology Promises to be the Next “Big Thing” In Biotechnology Purpose of the Report Immuno-oncology has been the hottest area in biotechnology in 2014 and this promises to continue in 2015 and the coming decade. This report attempts to provide a basic background to give readers a layman’s view of some of the new technologies […]